COVID-19
The knowledge on COVID-19 is changing and evolving rapidly, with novel insights and recommendations, almost on a daily basis. It behooves the medical community to provide updated information on a regular basis, on best practice to facilitate optimal care of infected patients and appropriate advice for the general population. This is particularly important in the case of patients with chronic conditions, such as Inflammatory Bowel Disease (IBD).
In the below mentioned paper, the ECCO compiled the existing evidence on the impact of COVID-19 in IBD patients and provide guidance and on the most appropriate care to adopt during the pandemic. Their review highlighted that IBD, per se, is not a risk factor for COVID-19. However, all IBD patients with symptoms should be tested for SARS-CoV-2 and the procedures for disease management shall be carefully adapted: i) in SARS-CoV-2 positive IBD patients, medical treatments should be re-evaluated (with particular focus on corticosteroids) always with the purpose of treating active disease and maintaining remission; ii) non-urgent surgeries and endoscopic procedures should be postponed for all patients; iii) online consultancy should be implemented; and iv) hospitalization and surgery should be limited to life threatening situations
IBDnet Webinar
For HCPs
Due to many uncertainties and upcoming questions we would like to invite you to this Webinar, trying to address some question on IBD management during COVID-19 pandemic. The faculty will be represented by Prof. Dr. med. Stephan Vavricka (ZGH), Prof. Dr. med. Pierre Michetti (La Source), Prof. Dr. med. Pascal Juillerat (Insel Bern) and Prof. Dr. med. Alain Schöpfer (CHUV).
Recorded sessions
For Patients
Due to many uncertainties and upcoming questions, we would like to invite you to this Webinar, trying to answer some questions about COVID-19 and CED (chair: Dr. med. Stephan Vavricka).
Recorded sessions
ECCO Statements
The aim of the current document is to provide to health care professionals some understanding and knowledge on the best care we can offer to our patients in general and particularly those underimmunosuppressive/ immunomodulatory treatment in the current situation of the COVID-19 epidemy.
1st ECCO Statement
2nd ECCO Statement
3rd ECCO Statement
4th ECCO Statement
5th ECCO Statement
6th ECCO Statement
SECURE-IBD Registry: Impact of COVID-19 on IBD patients
Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) is an international, pediatric and adult registry to monitor and report on outcomes of COVID-19 occurring in IBD patients. We encourage IBD clinicians worldwide to report ALL cases of COVID-19 in their IBD patients, regardless of severity (including asymptomatic patients detected through public health screening).
With the collaboration of our entire IBD community, we will rapidly be able to define the impact of COVID-19 on patients with IBD and how factors such as age, comorbidities, and IBD treatments impact COVID outcomes.
Visit SECURE-IBD
Review reported cases and outcomes
Report your case